概括
血管扩张剂普拉佐辛在患有慢性左心室衰竭的患者中显著改善了运动持续时间和心脏功能. 与安慰剂相比,普拉佐辛在这个患者群体中表现出更高的疗效.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性左心室衰竭 (CLVF) 显著影响患者的生活质量和预后.
- 标准疗法,包括数字和利尿剂,可能无法完全恢复心脏功能或运动能力.
研究的目的:
- 在患有CLVF的患者中,评估血管扩张剂普拉佐辛与安慰剂的疗效.
- 评估普拉佐辛对运动持续时间和左心室功能的影响.
主要方法:
- 这是一项双盲随机研究,涉及24名患有CLVF的患者.
- 患者接受了普拉佐辛或安慰剂,除了他们现有的数字和利尿药疗法外.
- 使用心声学来评估左心室功能,并通过跑步机持续时间来测量运动耐受性.
主要成果:
- 普拉佐辛降低了静止血压和心率-压力产品.
- 接受普拉佐辛治疗的患者表现出改善的临床症状,心胸比率降低,左心室和心房尺寸降低,射出分数和Vcf增强.
- 所有接受普拉佐辛治疗的患者在跑步机上运动的持续时间都经历了≥20%的改善,而安慰剂组没有任何改善. 肺静脉堵塞在50%的普拉佐辛患者中得到解决.
结论:
- 在患有慢性左心力衰竭的患者中,普拉佐辛有效地改善了运动能力和左心室功能.
- 普拉佐辛为管理CLVF提供了潜在的治疗益处,补充了现有的治疗方法.
更多相关视频
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
07:49A Pacing-Controlled Procedure for the Assessment of Heart Rate-Dependent Diastolic Functions in Murine Heart Failure Models
Published on: July 21, 2023
相关概念视频
Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure III: Clinical Manifestations
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
